J. uno Therapeutics is abandoning a cancer therapy that once looked like a revolutionary advance, reacting to a rash of patient deaths that made the customized treatment too risky to push forward.
The company’s decision changes the landscape in a blockbuster race to commercialize the first CAR-T technology, a promising new approach to cancer in which patients’ own immune cells are rewired to attack tumors.
Juno, once a leader in the field, is now more than a year behind rivals Kite Pharma and Novartis. This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today.
It’s easy! Your first 30 days are free and if you don’t enjoy your subscription you can cancel any time.